Physician

Mhd Adnan Alsaka, MD

According to 2025 Medicare claims, Mhd Alsaka, MD (NPI: 1184880049) practices nephrology in the Florence, SC market, with the plurality of this provider's patient population coming from Florence, SC. This provider's primary affiliated billing organization is FLORENCE NEPHROLOGY ASSOCIATES, LLC (NPI: 1235871146; TIN: 873650708) and primary practice location at 29506-2617. Alsaka is affiliated with the McLeod Healthcare Network, LLC (ACO ID: A3677), participating under the MSSP model.

Alsaka's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 383 traditional Medicare patients, billed 2,148 HCPCS/CPT codes, and received $201,420 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,356 prescription claims across 255 beneficiaries totaling $183,572 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 80 claims. Open Payments data shows 1 records totaling $24. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $65,925 to $201,420. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $77,818 to $183,572. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,270 and ending at $1,882.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	263	844	$65,925
2016	376	2,178	$149,298
2017	426	2,720	$199,510
2018	621	3,335	$241,953
2019	712	3,346	$248,381
2020	747	3,190	$287,794
2021	695	2,863	$285,872
2022	427	2,232	$224,801
2023	461	2,971	$277,646
2024	383	2,148	$201,420

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	860	$77,818
2016	123	950	$63,747
2017	179	1,671	$114,209
2018	292	2,221	$157,678
2019	282	1,984	$139,198
2020	248	1,810	$199,484
2021	293	1,763	$164,854
2022	238	1,404	$161,743
2023	233	1,088	$98,726
2024	255	1,356	$183,572

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$677
2016	N/R	12	$422
2017	N/R	11	$40
2018	N/R	22	$1,258
2019	N/R	61	$2,068
2020	N/R	52	$1,896
2021	N/R	22	$554
2022	N/R	80	$1,958
2023	N/R	94	$1,809
2024	N/R	80	$1,354

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	58	218	$244
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	139	189	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	177	321	$85
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	163	963	$56
90935	Hemodialysis procedure with physician evaluation	34	102	$49

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	84	2,820	$52,048
Jardiance	Empagliflozin	44	1,350	$26,841
Veltassa	Patiromer Calcium Sorbitex	23	748	$25,297
Auryxia	Ferric Citrate	17	510	$23,939
Lokelma	Sodium Zirconium Cyclosilicate	33	1,048	$22,880

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	25	$540
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$339
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$288
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	12	$187

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$24	AKEBIA THERAPEUTICS INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mhd Adnan Alsaka, MD?

Tedicare shows public-source Medicare data for Mhd Adnan Alsaka, MD (NPI 1184880049), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mhd Adnan Alsaka, MD have ACO affiliation data?

Mhd Adnan Alsaka, MD is shown with ACO affiliation data for McLeod Healthcare Network, LLC (MSSP, ACO ID A3677).

What billing organization is linked to Mhd Adnan Alsaka, MD?

Mhd Adnan Alsaka, MD is linked to FLORENCE NEPHROLOGY ASSOCIATES, LLC (billing NPI 1235871146) in the available physician profile data.

Does Mhd Adnan Alsaka, MD have Open Payments data?

Mhd Adnan Alsaka, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.